03:21:58 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-29 Kvartalsrapport 2024-Q3
2024-08-30 Kvartalsrapport 2024-Q2
2024-05-31 Kvartalsrapport 2024-Q1
2024-05-29 Ordinarie utdelning POLAR 0.00 SEK
2024-05-28 Årsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-11-24 Kvartalsrapport 2023-Q3
2023-09-08 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-26 Kvartalsrapport 2023-Q1
2023-05-17 Årsstämma 2023
2023-05-05 Ordinarie utdelning POLAR 0.00 SEK
2023-03-13 Extra Bolagsstämma 2022
2023-02-24 Bokslutskommuniké 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-27 Kvartalsrapport 2022-Q1
2022-05-06 Ordinarie utdelning POLAR 0.00 SEK
2022-05-05 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-28 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning POLAR 0.00 SEK
2021-05-05 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning POLAR 0.00 SEK
2020-06-30 Årsstämma 2020
2020-05-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2020-02-14 Extra Bolagsstämma 2020
2019-10-23 Kvartalsrapport 2019-Q3
2019-07-24 Kvartalsrapport 2019-Q2
2019-05-07 Split POLAR 16:1
2019-04-26 Kvartalsrapport 2019-Q1
2019-03-19 Årsstämma 2019
2019-02-04 Ordinarie utdelning POLAR 0.00 SEK
2019-02-01 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Polarcool är verksamt inom medicinteknik. Idag är bolaget inriktade mot att produkter och lösningar inriktade för skador inom sport och aktivitet. Störst fokus återfinns inom forskning och utveckling av produkter som används vid behandling av hjärnskador vid exempelvis boxning, rugby och amerikansk fotboll. Verksamhet innehas på global nivå, med störst närvaro inom den europeiska marknaden.
2023-01-11 09:31:00

The med-tec company PolarCool AB (publ) continues to establish the PolarCap® in ice hockey, by signing a two-year agreement with Norwegian ice hockey giant Vålerenga Ishockey.

PolarCool develops and markets PolarCap®, which alleviates the effects of concussion. The primary users of PolarCap® include sports clubs, organizations, and facilities in contact sports such as ice hockey, rugby, football, and handball, as well as other sports with an increased risk of concussion.

The company has a strong foothold in Swedish ice hockey, having a league-wide agreement with the SHL, as well as many agreements with 2[nd] and 3[rd] tier Swedish teams. In addition, the establishment of PolarCap® has continued in European ice hockey, with PolarCap now being used by ice hockey teams across five countries - Sweden, Finland, Norway, Switzerland, and Germany.

The agreement with Vålerenga has important strategic value as it is the company's first agreement on the Norwegian market, even if the financial significance of individual agreements is limited. Vålerenga Hockey will use the PolarCap System for the rest of the 2023 season in an initial evaluation period, with the option to continue into a two-year commercial agreement following the season.

Vålerenga Hockey's Dr. Anine Nordström comments;

-I am happy that we at Vålerenga Hockey will be able to include the PolarCap System in our routines managing concussions and look forward to getting first-hand experiences.

PolarCool CEO Erik Andersson comments;

-I am pleased that we are progressing into new markets. Our first agreement in Norway is very positive and we now look forward to the continued establishment in this market. Our ambition is for more Norwegian teams to follow and we will also start conversations on the league level to work for a league-wide agreement for next season.

The capital club Vålerenga Ishockey plays in the Norwegian top league, the Fjortkraft league, and the club is one of the most successful in Norwegian hockey with 30 league titles and famous players such as Espen "Shampo" Knutsen.